"FDA Approves Groundbreaking Gene Therapies for Sickle Cell Anemia, Paving the Way for a Cure"
The FDA has approved the first gene therapies, Casgevy and Lyfgenia, for sickle cell anemia. Casgevy, which utilizes the CRISPR gene editing tool, will cost $2.2 million, while Lyfgenia will cost $3.1 million. These treatments offer potential cures for the disease by modifying and transplanting blood stem cells. However, the high cost raises concerns about accessibility for patients, despite the potential benefits.